<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134184</url>
  </required_header>
  <id_info>
    <org_study_id>SU-25199</org_study_id>
    <secondary_id>1U19AI090019-01</secondary_id>
    <nct_id>NCT02134184</nct_id>
  </id_info>
  <brief_title>The Influence of Chronic CMV Infection on Influenza Vaccine Responses</brief_title>
  <acronym>SLVP025</acronym>
  <official_title>The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we are trying to understand whether previous infection with a particular virus,
      namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new
      infections or vaccinations with age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators want to compare the T- and B-cell response to conventional intramuscular
      trivalent influenza vaccine (TIV) in elderly individuals dependent on the presence and
      duration of CMV infection by analyses of vaccine-induced plasmablasts, antibodies and
      antigen-specific T cells. Healthy volunteers, &gt; 60 years of age, will be identified by the
      Stanford Blood Center based on their history of positive or negative CMV serologies. Baseline
      blood samples will be drawn from all study participants prior to immunization. All
      participants will receive a single dose of 2012-2013 licensed TIV. Volunteers will complete 3
      study visits at Day 0, Day 7 and Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants From Each Arm Who Received Influenza Vaccine</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To Compare the T- and B-cell Response to Licensed IM TIV in Elderly Individuals Dependent on the Presence and Duration of CMV Infection by Analyses of Vaccine-induced Plasmablasts, Antibodies and Antigen-specific T Cells</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CMV negative group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMV positive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recent CMV Converters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® 2012-2013 Formula NDC No 498281-012-50</intervention_name>
    <description>This vaccine is given intramuscularly</description>
    <arm_group_label>CMV negative group</arm_group_label>
    <arm_group_label>CMV positive group</arm_group_label>
    <arm_group_label>Recent CMV Converters</arm_group_label>
    <other_name>Trivalent inactivated influenza vaccine (TIV)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy, ambulatory adult 60 years of age or above.

          -  Self-identified by a participant after notification by Stanford Blood Center (SBC) of
             their group assignment based review of SBC CMV data:

               -  CMV-negative: Donor has donated at least twice during the last 3 years AND
                  donor's most recent two donations tested CMV antibody negative.

               -  CMV positive longstanding infection: Donor has donated at least once within the
                  &quot;recent&quot; timeframe (past three years) AND donor's most recent donation tested CMV
                  antibody positive AND donor had at least one donation prior to 2000 that tested
                  CMV antibody positive.

               -  Recent CMV converters: Donor has donated at least once within the &quot;recent&quot;
                  timeframe (past three years) AND donor's most recent two donations tested CMV
                  antibody positive AND donor had at least two CMV negative donations in the past.

          -  Willing to complete the informed consent process.

          -  Availability for follow-up for the planned duration of the study at least 28 days
             after immunization.

          -  Acceptable medical history by review of inclusion/exclusion criteria and vital signs.

        Exclusion Criteria:

          -  Prior off-study vaccination with the current 2012-2013 seasonal influenza vaccine

          -  Allergy to egg or egg products, or to vaccine components or thimerosal (TIV multidose
             vials only)

          -  Life-threatening reactions to previous influenza vaccinations.

          -  Active systemic or serious concurrent illness, including febrile illness on the day of
             vaccination

          -  Weight less than 110 lbs

          -  History of immunodeficiency (including HIV infection)

          -  Known or suspected impairment of immunologic function, including, but not limited to,
             clinically significant liver disease, diabetes mellitus treated with insulin, moderate
             to severe renal disease, or any other chronic disorder which, in the opinion of the
             investigator, might jeopardize volunteer safety or compliance with the protocol.

          -  Blood pressure &gt;150 systolic or &gt;95 diastolic at first study visit

          -  Hospitalization in the past year for congestive heart failure or emphysema.

          -  History of chronic Hepatitis B or C.

          -  Recent or current use of immunosuppressive medication, including systemic
             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in
             all groups)

          -  Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
             such as breast cancer or prostate cancer with recurrence in the past year, and any
             hematologic cancer such as leukemia).

          -  Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
             of the investigator, might jeopardize volunteer safety or compliance with the
             protocol.

          -  History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
             medical follow up or hospitalization during the preceding year

          -  Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
             agents such as aspirin (except up to 325 mg aspirin per day), Plavix, or Aggrenox must
             be reviewed by investigator to determine if this would affect the volunteer's safety.

          -  Receipt of blood or blood products within the past 6 months or planned receipt of
             blood products prior to completion of study visits.

          -  Medical or psychiatric condition or occupational responsibilities that preclude
             participant compliance with the protocol

          -  Inactivated vaccine 14 days prior to vaccination or planned non-study vaccination
             prior to completion of Visit 03 (~Day 28 after the study vaccination)

          -  Live, attenuated vaccine within 60 days of vaccination or planned non-study
             vaccination prior to completion of Visit 03 (~Day 28 after the study vaccination)

          -  Need an allergy immunization (that cannot be postponed) during the study period V01 to
             V03 (~Day 28)

          -  History of Guillain-Barré Syndrome

          -  Use of investigational agents within 30 days prior to enrollment or planned use of
             investigational agents prior to completion of study visits

          -  Donation of the equivalent of a unit of whole blood within 6 weeks or a unit of
             platelets within 2 weeks prior to enrollment or planned blood donation prior to
             completion of study visits.

          -  Any condition which, in the opinion of the investigator, might interfere with
             volunteer safety, study objectives or the ability of the participant to understand or
             comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Dekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorg J Goronzy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vaccines.stanford.edu/completed_studies.html</url>
    <description>Stanford LPCH Vaccine Program Clinical Trials Website</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <results_first_submitted>December 16, 2016</results_first_submitted>
  <results_first_submitted_qc>December 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 26, 2016</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Cornelia L. Dekker</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CMV Negative Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
        </group>
        <group group_id="P2">
          <title>CMV Positive Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
        </group>
        <group group_id="P3">
          <title>Recent CMV Converters</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly Recent CMV Conversion is defined as: Donor has donated at least once within the &quot;recent&quot; timeframe (past three years) AND donor's most recent two donations tested CMV antibody positive AND donor had at least two CMV negative donations in the past</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CMV Negative Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
Fluzone® 2012-2013 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="B2">
          <title>CMV Positive Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
Fluzone® 2012-2013 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="B3">
          <title>Recent CMV Converters</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
Fluzone® 2012-2013 Formula: This vaccine is given intramuscularly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.96" spread="4.52"/>
                    <measurement group_id="B2" value="67.46" spread="5.26"/>
                    <measurement group_id="B3" value="66.75" spread="3.53"/>
                    <measurement group_id="B4" value="67.21" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants From Each Arm Who Received Influenza Vaccine</title>
        <time_frame>Day 0 to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CMV Negative Group</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>CMV Positive Group</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Recent CMV Converters</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants From Each Arm Who Received Influenza Vaccine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <time_frame>Day 0 to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CMV Negative Group</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>CMV Positive Group</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
          <group group_id="O3">
            <title>Recent CMV Converters</title>
            <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Compare the T- and B-cell Response to Licensed IM TIV in Elderly Individuals Dependent on the Presence and Duration of CMV Infection by Analyses of Vaccine-induced Plasmablasts, Antibodies and Antigen-specific T Cells</title>
        <time_frame>Day 0 to Day 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 28 of study participation</time_frame>
      <desc>Clinical Assessment performed at each visit</desc>
      <group_list>
        <group group_id="E1">
          <title>CMV Negative Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
        </group>
        <group group_id="E2">
          <title>CMV Positive Group</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
        </group>
        <group group_id="E3">
          <title>Recent CMV Converters</title>
          <description>Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
This vaccine is given intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Community Acquired Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cornelia Dekker</name_or_title>
      <organization>Stanford University School of Medicine, Dept. of Pediatrics</organization>
      <phone>650-724-4437</phone>
      <email>cdekker@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

